Annexon anticipates a Biologics License Application (BLA) submission for ANX005 in the first half of 2025, potentially transforming Guillain-Barré Syndrome (GBS) treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.